for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA® (pembrolizumab)

March 14 (Reuters) - Merck & Co Inc

* Merck provides update on supplemental biologics license application (sbla) for keytruda® (pembrolizumab) in previously treated advanced microsatellite instability-high cancer

* Merck & co inc - new fda target action date is june 9, 2017

* Merck & co-submission of additional data is considered major amendment to sbla under pdufa, thus extending target action date by three months Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up